Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 4, 2012, Pages 374-381

  Frønsdal, Katrine ^a   Pichler, Franz ^b   Mardhani Bayne, Logan ^c   Henshall, Chris ^d   Røttingen, John Arne ^a   Mørland, Berit ^a   Klemp, Marianne ^a  

^a Norwegian Knowledge Centre for Health Services (NOKC)   (Norway)

^b Centre for Innovation in Regulatory Science (CIRS)   (United Kingdom)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Biomedical; Decision making; Health; health insurance; Health policy; Insurance coverage; Regulatory approval; Reimbursement; Technology assessment

Indexed keywords

BIOMEDICAL; HEALTH POLICY; REGULATORY APPROVAL; REIMBURSEMENT; TECHNOLOGY ASSESSMENTS;

DECISION MAKING; HEALTH INSURANCE; INDUSTRY; INNOVATION;

HEALTH;

ARTICLE; AUSTRALIA; CANADA; DEVICES; DRUG RESEARCH; EUROPE; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH STATUS; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; INDUSTRY; MEDICAL INFORMATION; PRACTICE GUIDELINE; SWEDEN; UNITED KINGDOM; UNITED STATES;

CANADA; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; GOVERNMENT REGULATION; GREAT BRITAIN; HEALTH POLICY; HUMANS; INSURANCE COVERAGE; INTERNATIONALITY; SWEDEN; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 84867527693     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000591     Document Type: Article

References (25)

1. Australian Government Department of Health and Ageing, Public Benefits Scheme (PBS). Framework for the introduction of parallel TGA and PBAC processes. http://www.pbs.gov.au/infopublication/factsheets/shared/framework-for- introduction-of-parallel-TGA-and-PBAC-processes (accessed August 2011).
2. Breckenridge A, Woods K, Walley T. Medicine's regulation and health technology assessment. Clin Pharmacol Ther. 2010;87:152-154.
3. Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review Submission Guidelines for Manufacturers. http://cadth. ca/media/cdr/process/CDR-Submission-Guidelines.pdf (accessed August 2011).
4. Centre for Innovation in Regulatory Science (CIRS). http://www.cirsci.org (accessed August 2011).
5. Centre for Innovation and Regulatory Sciences (CIRS). Evidentiary requirements in clinical development: Synchronising phase III requirements to multiple needs. http://www.cirsci.org/system/files/private/1031% 20March%20WS%20synopsis-3May.pdf (accessed August 2011).
6. Eichler H, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277-291.
7. European Medicines Agency (EMA). http://www.ema.europa.eu/(accessed August 2011).
8. European Medicines Agency (EMA). European Public Assessment Report (EPAR) contribution to relative effectiveness assessments. http://www.ema.europa.eu/ docs/en-GB/document-library/Press-release/2010/02/WC500073909.pdf (accessed August 2011).
9. European network for HTA (EUnetHTA). EUnetHTA JA WP5: Relative Effectiveness Assessment (REA) of Pharmaceuticals. http://www.eunethta.net/ upload/WP5/Link1.pdf (accessed August 2011).
10. European network for HTA (EUnetHTA). EUnetHTA WP5: Relative Effectiveness Assessment (REA) of Pharmaceuticals. Pilot assessment using the draft rapid REA model. http://www.eunethta.eu/upload/WP5/Public%20consultations2012/ PC%20June%206%202012/Pazopanib% 20report%203rd%20version-120606%20(1).pdf (accessed June 2012).
11. European Union High Level Pharmaceutical Forum. http://ec.europa. eu/pharmaforum/(accessed October 2011).
12. Executive Agency for Health and Consumers (EAHC). http://ec.europa. eu/eahc/documents/health/tenders/2010/EN/EAHC-2010-05-contract-award-notice.pdf (accessed November 2011).
13. Executive Agency for Health and Consumers (EAHC). Final CAVOD study report. Creation of a process for the exchange of knowledge between Member States and European authorities on the scientific assessment of the clinical added value for orphan medicines. http://ec.europa.eu/eahc/documents/news/CAVOD- Final%20Report-vf-corrected-281011.pdf (accessed June 2012).
14. Food and Drug Administration (FDA). http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm274833.htm (accessed June 2012).
15. Food and Drug Administration (FDA). Memorandum of understanding between United States Food and Drug Administration and Centers for Medicare & Medicaid Services. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/ MemorandaofUnderstandingMOUs/DomesticMOUs/ucm217585.htm (accessed August 2011).
16. Green Park Collaborative (GCP): http://www.htai.org/index.php?id=703 (accessed June 2012).
17. Health Technology Assessment International (HTAi). http://www.htai.org (accessed August 2011).
18. Health technology Assessment International (HTAi) and the international network of agencies for health technology assessment (INAHTA). HTA Glossary. http://www.htaglossery.net (accessed August 2011).
19. Health Technology Assessment International (HTAi). Policy Forum. http://www.htai.org/index.php?id=643 (accessed August 2011).
20. Henshall C, Mardhani-Bayne L, Fronsdal KB, Klemp M. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care. 2011;27:253-260.
21. Liberti LE, Pichler F, Walker S. Preparing for regulatory review and reimbursement decisions: A case for cooperation between regulatory authorities, sponsors and health technology assessment agencies. Pharm Med. 2009;23:263-267.
22. Medical Products Agency (MPA).Joint scientific advice meetings between the Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Products Agency (MPA). http://www.lakemedelsverket.se/english/product/Medicinal-products/ Scientific-advice/Pilot-project-of-joint-scientific-advice-meetings-arranged-by- the-TLV-and-the-MPA/ (accessed August 2011).
23. Medicine Evaluation Committee (MEDEV). http://www.esip.org/files/pb51-0- 0.pdf (accessed October 2011).
24. Medicines and Healthcare products Regulatory Agency (MHRA). Vo l-untary parallel scientific advice with NICE and the MHRA. http://www.mhra.gov.uk/ Howweregulate/Medicines/Medicinesregulatorynews/CON076350 (accessed August 2011).
25. Tapestry Networks. Pilots of multi-stakeholder consultations in early-stage drug development frequently asked questions. http://www. tapestrynetworks.com/documents/EHILN-multi-stakeholder%20pilots% 20FAQs%20-%2010-19-10.pdf (accessed June 2012).